| 02-05 |
|
13748 |
|
| 02-05 |
For immunochemical analysis of MyD88
Antigen:
synthetic peptide corresponding to human MyD88 amino acids 233-248
·
Host:
rabbit
·
Application(s):
WB
·
|
13746 |
|
| 02-05 |
For immunochemical analysis of NF-κB (p50)
Antigen:
a portion of amino acids 150-200 of human NF-κB (p50)
·
Clone designation:
2J10D7
·
Isotype:
IgG1κ
·
Application(s):
IHC and WB
·
|
13755 |
|
| 02-05 |
An aconitase inhibitor
Oxalomalic acid, formed by the condensation of oxaloacetate with glyoxylate in vivo, inhibits both aconitase and NADP-dependent isocitrate dehydrogenase in the conversion of citrate to isocitrate at concentrations as low as 1 mM. At 5 mM, oxalomalic acid inhibition of aconitase leads to a decrease in the binding activity of IRP1 and a decrease in glutamate secretion in cultured lens epithelial cells, retinal pigment epithelial cells, and neurons.
|
13521 |
|
| 02-05 |
An inhibitor of Ewing’s sarcoma tumors
YK-4-279 is an inhibitor of protein-protein interactions between ES-FLI1 and RHA. At 10 µM, YK-4-279 blocks RHA binding to ES-FLI1 and induces apoptosis of a panel of Ewing’s sarcoma tumor cell lines with IC50 values ranging from 0.5 to 2 µM. At 1.5 mg per dose, YK-4-279 reduces the growth of Ewing’s sarcoma orthotopic xenografts in mice after treatment with the inhibitor for two weeks.
|
13661 |
|
| 02-03 |
A dopamine precursor used to treat Parkinson’s Disease
L-DOPA is a metabolic precursor of dopamine that is capable of crossing the blood brain barrier. It is produced from L-tyrosine by trysosine hydroxylase and metabolized by catechol-O-methyl transferase (COMT) . In the brain L-DOPA is converted to dopamine. It is conventionally used to increase dopamine concentrations in the brain as a treatment for Parkinson’s disease and stroke recovery. However L-DOPA has a short half-life and is known to elevate homocysteine concentrations in plasma, which can be neurotoxic and induce oxidative damage.
|
13248 |
|
| 02-02 |
Analog of PGJ2
13,14-dihydro-16,16-difluoro PGJ2 is an analog of PGJ2. While its biological activities have not been evaluated, it should be noted that the addition of two electron-withdrawing fluorine atoms has been used to stabilize prostanoids and significantly delay degradation in vivo. Importantly, 13,14-dihydro PGE1 has activity that is comparable to that of PGE1, suggesting that this analog of PGJ2 could be biologically active.
|
13635 |
|
| 02-02 |
An internal standard for the quantification of 6,15-diketo-13,14-dihydro PGF1α
6,15-diketo-13,14-dihydro PGF1α is a metabolite of PGI2. It was shown to enhance intracellular cAMP and cholesterol catabolism in bovine arterial smooth muscle cells.
|
9000525 |
|
| 02-02 |
Selective EP1 antagonist
SC-51089 is a selective EP1 antagonist, first shown to have in vivo analgesic activity in mice (ED50 = 6.3 mg/kg when given subcutaneously) and in the rat. SC-51089 also inhibits the growth of glioma cell lines in vitro (IC50 = ~1 μM) and slows tumor growth in vivo. In addition, SC-51089 is neuroprotective, attenuating neuronal cell death in response to oxidative stress, an effect that is also found in EP1-/- mice and mediated by PGE2.
|
10011561 |
|
| 02-02 |
A potent RTK inhibitor
SU 11652 is a potent, cell-permeable, and ATP-competitive inhibitor of the tyrosine kinase activity of several GFRs, including platelet-derived GFR (PDGFR-β; IC50 = 3 nM), vascular endothelial GFR (VEGFR-2; IC50 = 27 nM), and fibroblast GFR (FGFR1; IC50 = 170 nM), but not epidermal GFR (IC50 > 20 μM). SU 11652 also potently inhibits wild-type Kit in mast cells (IC50 = 50 nM) and stops cell cycling while inducing apoptosis in cells expressing constitutively-active kit mutants. Furthermore SU 11652 reduces angiogenesis induced by estrogen in mice.
|
13577 |
|
| 01-29 |
A carotenoid with anti-obesity actions
Fucoxanthin is a carotenoid that occurs naturally in certain algae. It significantly reduces abdominal white adipose tissue (WAT) in mice and rats when included in their diet. Fucoxanthin also increases the amount of mitochondrial uncoupling protein 1 (UCP1), a fatty acid-stimulated protein involved in respiration and thermogenesis in WAT of mice and rats. In KK-Ay mice, which are used to model obese type 2 diabetics with hyperinsulinemia, fucoxanthin reduces WAT gain and also decreases blood glucose and plasma insulin levels.
|
13068 |
|
| 01-27 |
Analog of PGD2
13,14-dihydro-16,16-difluoro PGD2 is an analog of PGD2. While its biological activities have not been evaluated, it should be noted that the addition of two electron-withdrawing fluorine atoms has been used to stabilize prostanoids and significantly delay degradation in vivo. Importantly, 13,14-dihydro PGE1 has activity that is comparable to that of PGE1, suggesting that this analog of PGD2 should be biologically active.
|
13612 |
|
| 01-27 |
Analog of PGF2α
13,14-dihydro-16,16-difluoro PGF2α is an analog of PGF2α. While its biological activities have not been evaluated, it should be noted that the addition of two electron-withdrawing fluorine atoms has been used to stabilize prostanoids and significantly delay degradation in vivo. Importantly, 13,14-dihydro PGE1 has activity that is comparable to that of PGE1, suggesting that this analog of PGF2α could be biologically active.
|
13609 |
|
| 01-27 |
Potent, selective inhibitor of Rho kinase II (ROCK-II)
Rho Kinase Inhibitor IV is a selective and potent Rho kinase inhibitor (IC50 = 11.8 nM for ROCK-II). It is a glycylated isoquinoline compound derived from the therapeutically-important ROCK inhibitor HA-1077 (Fasudil hydrochloride) and exhibits better specificity. Thus, it poorly inhibits calcium/calmodulin kinase II, protein kinase G, and Aurora A (IC50 = 2.57, 2.35, and 3.26 μM, respectively) as well as PKA or PKC (IC50 > 10 μM for each). The potency of Glycyl-H-1152 is superior to that of other ROCK inhibitors, including Y-27632 (Ki = 220 nM) and HA-1077 (IC50 = 158 nM).
|
13332 |
|
| 01-27 |
Inhibitor of FAAH
PF-3845 is a potent, selective, and irreversible inhibitor of FAAH (Ki = 0.23 μM). It covalently binds FAAH on Ser241 at the catalytic site, resulting in prolonged elevation of AEA in the brain and plasma in rats after treatment. PF-3845 significantly and persistently reduces inflammatory pain in rats through a cannabinoid receptor-dependent mechanism.
|
13279 |
|
| 01-25 |
Selective inhibitor of PI3Kγ
AS 041164 is a potent inhibitor of PI3K with selectivity for the class IB isoform PI3Kγ (IC50 = 70 nM), compared to PI3Kα (IC50 = 240 nM), PI3Kβ (IC50 = 1.45 μM), and PI3Kδ (IC50 =1.70 ). When tested at 1.0 μM, it shows little or no activity against 38 other common kinases. When given orally to mice, AS 041164 shows a pharmacokinetic profile that is similar to the general PI3K inhibitor LY294002 but is three times more potent (ED50 = 27.35 mg/kg for AS 041164 versus 81.59 mg/kg for LY294002) in blocking neutrophil recruitment induced by RANTES.
|
13622 |
|
| 01-25 |
An antibacterial and immunosuppressant
Celastramycin A is a bioactive compound isolated from endophytic bacteria living in plants of the Celastraceae family. This benzoyl pyrrole inhibits the growth of bacteria and mycobacteria, with a minimal inhibitory concentration as low as 0.05 μg/ml. Celastramycin A also suppresses the production of IL-8 in human umbilical vein endothelial cells as stimulated by TNF-α (IC50 = 0.01 μg/ml).
|
13519 |
|
| 01-25 |
Antigen:
human CMKLR1 amino acids 358–371 (NERTSMNERETGML)
·
Host:
rabbit
·
Peptide sequence:
WB, FC, and IHC
·
|
10325 |
|
| 01-21 |
Estrogen receptor modulator
Tamoxifen is a selective estrogen receptor modulator, evoking tissue-dependent effects. It is an antagonist of ER action in breast tissue and breast cancer cells and is effective in the treatment of early breast cancer to prevent tumor growth. Importantly, tamoxifen acts as an ER agonist in bone and blood vessels, helping to minimize osteoporosis and reduce the risk of cardiovascular disease in post-menopausal women. Also, tamoxifen is a partial ER agonist in uterine tissues and increases the risk of endometrial carcinoma.
|
13258 |
|
| 01-20 |
An internal standard for the quantification of PEA
|
9000551 |
|
| 01-19 |
An H2S-releasing latanoprost analog
ACS 67 is an analog of latanoprost (free acid) that contains a hydrogen sulfide releasing component conjugated to the latanoprost carboxyl group. In glaucomatous pigmented rabbits, ACS 67 reduced intra-ocular pressure (IOP) more rapidly and to a greater extent than latanoprost (15 versus 25.5 mm Hg at 4 hours) at a dose of 0.005% for each compound. ACS 67 also increased the levels of reduced glutathione and cGMP in the aqueous humor of glaucomatous pigmented rabbits better than latanoprost.
|
13619 |
|
| 01-19 |
For immunochemical analysis of Akt3
Antigen:
synthetic peptide from human Akt3 amino acids 119-136 (CSPTSQIDNIGEEEMDAS); this sequence is identical in human, murine, rat, ovine, canine, and chicken
·
Clone designation:
66C1247.1
·
Host:
mouse
·
Isotype:
IgG1
·
Application(s):
WB
·
|
13736 |
|
| 01-19 |
Antigen:
human GPR17 amino acids 351-367 (SFEGKTNESSLSAKSEL)
·
Host:
rabbit
·
Peptide sequence:
WB, FC, and ICC
·
|
10136 |
|
| 01-19 |
Antigen:
human GPR55 amino acids 207-219 (ILLGRRDHTQDWV)
·
Host:
rabbit
·
Application(s):
WB, FC, and ICC
·
|
10224 |
|
| 01-18 |
For immunochemical analysis of Akt3
Antigen:
synthetic peptide from human Akt3 amino acids 119-136; this sequence is identical in human, murine, and rat
·
Host:
rabbit
·
Application(s):
WB
·
|
13737 |
|
| 01-18 |
Peptide to block Akt1, Akt2, and Akt3 kinase activity
Akt is a protein kinase that plays a central role in inhibiting apoptosis through promoting cell survival. Activated Akt functions by phosphorylating downstream targets in survival signaling pathways. TCL1 (a proto-oncogene underlying human T-cell prolymphocytic leukemia) interacts with Akt through an N-terminal pleckstrin homology (PH) domain and functions as an Akt kinase co-activator. This inhibitory peptide interacts with Akt. The peptide binds to the PH domain of Akt and inhibits Akt1, Akt2, and Akt3 kinase activity. The Akt (Isoforms 1, 2, 3) inhibitory peptide also contains a protein transduction (PTD) sequence (DRQIKIWFQNRRMKWKK) derived from antennapedia which renders the peptide cell permeable. The control peptide consists of only the PTD sequence.
|
13738 |
|
| 01-18 |
For immunochemical analysis of FoxP3/Scurfin
Antigen:
synthetic peptide corresponding to the exon 2 deletion site was used as immunogen
·
Host:
rabbit
·
Application(s):
IHC and WB
·
|
13739 |
|
| 01-18 |
For immunochemical analysis of FoxP3Δ2
Antigen:
synthetic peptide corresponding to the exon 2 deletion site
·
Clone designation:
16J4G6
·
Host:
Mouse
·
Isotype:
IgMκ
·
Application(s):
WB
·
|
13744 |
|
| 01-18 |
For immunochemical analysis of FoxP3Δ2
Antigen:
synthetic peptide corresponding to the exon 2 deletion sit
·
Clone designation:
16J4G6
·
Host:
mouse
·
Isotype:
IgMκ
·
Application(s):
WB
·
|
13743 |
|
| 01-15 |
A flow cytometric assay to assess cell proliferation
Cayman’s CFSE Cell Division Assay Kit provides an easy to use format for labeling and tracing cells through successive cell divisions which can be used to study the induction and inhibition of cell division in any in vitro model. The kit contains sufficient reagents for labeling and analyzing 100 cell samples by flow cytometry. CFSE can also be combined with any fluorochrome compatible with fluorescein for use in flow cytometry.
|
10009853 |
|
| 01-14 |
High-affinity cannabinoid receptor agonist
JWH 019 is a cannabimimetic indole that shows a high-affinity for both the central cannabinoid (CB1) and the peripheral cannabinoid (CB2) receptors. The affinities of JWH 019 for both CB1 (Ki = 9.8 nM) and CB2 (Ki = 5.6 nM) are superior to those of the traditional cannabinoid, Δ9-tetrahydrocannabinol (Δ9-THC; Ki values of 40.7 and 36.4 nM for CB1 and CB2, respectively).
|
13633 |
|
| 01-14 |
High-affinity cannabinoid receptor agonist
JWH 250 is a cannabimimetic indole that shows a high-affinity for both the central cannabinoid (CB1) and the peripheral cannabinoid (CB2) receptors. The affinities of JWH 250 for both CB1 (Ki = 11 nM) and CB2 (Ki = 33 nM) are comparable to those of the traditional cannabinoid, Δ9-tetrahydrocannabinol (Δ9-THC; Ki = 40.7 and 36.4 nM, respectively).
|
13634 |
|
| 01-13 |
An internal standard for the quantification of linoleoyl ethanolamide by GC- or LC-MS
|
9000553 |
|
| 01-12 |
For immunochemical analysis of Akt2/3
Antigen:
synthetic peptide from human Akt2 amino acids 319-331; this sequence is 100% homologus in Akt3
·
Host:
rabbit
·
|
13735 |
|
| 01-12 |
For immunochemical analysis of Akt2
Antigen:
synthetic peptide from human Akt2 amino acids 106-123
·
Clone designation:
95C567.1.2
·
Host:
mouse
·
Isotype:
IgM
·
Application(s):
WB
·
|
13734 |
|
| 01-12 |
Neruroprotective drug
Dimebon is an orally-available drug, approved in Russia for use as a non-selective antihistamine, that has shown promise in the treatment of neurodegenerative diseases, including Alzheimer’s and Huntington’s disease. In addition to preventing the onset and progression of disease by being neuroprotective, dimebon appears to promote clinical improvement by increasing cognitive function. At the cellular level, dimebon appears to have diverse effects, inhibiting the neurotoxic action of β-amyloid and blocking L-type calcium channels, inhibiting NMDA-type glutamate receptors, and preventing mitochondrial leakage.
|
9000556 |
|
| 01-12 |
An internal standard for the quantification of OEA by GC- or LC-MS
|
9000552 |
|
| 01-11 |
For immunochemical analysis of Akt1 (Phospho-Ser473)
Antigen:
synthetic peptide from human Akt1 containing phospho-serine473
·
Clone designation:
104A282
·
Host:
mouse
·
Isotype:
IgG2κ
·
Application(s):
IP and WB
·
|
13733 |
|
| 01-11 |
For immunochemical analysis of Akt1
Antigen:
synthetic peptide from human Akt1 amino acids 464-477; this peptide sequence is identical in human, murine, chicken, and frog
·
Host:
rabbit
·
Application(s):
WB
·
|
13732 |
|
| 01-07 |
Source:
recombinant N-terminal Histidine-tagged SET8 amino acids 190-352, purified from E. coli, NP-065115
·
Mr:
21.1 kDa
·
|
10319 |
|
